Benevolent AI (Benevolent AI) Debt-to-Asset : 0.04 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Benevolent AI Debt-to-Asset?

Benevolent AI's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.17 Mil. Benevolent AI's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.84 Mil. Benevolent AI's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $156.75 Mil. Benevolent AI's debt to asset for the quarter that ended in Dec. 2023 was 0.04.

Benevolent AI Debt-to-Asset Historical Data

The historical data trend for Benevolent AI's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benevolent AI Debt-to-Asset Chart

Benevolent AI Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.08

0.07

0.10

0.04

Benevolent AI Quarterly Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial				0.10	0.04	0.04	0.04	0.04

Competitive Comparison of Benevolent AI's Debt-to-Asset

For the Biotechnology subindustry, Benevolent AI's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Benevolent AI's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benevolent AI's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Benevolent AI's Debt-to-Asset falls into.

Benevolent AI Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Benevolent AI's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.171	+	4.839)	/	156.748
	=	0.04

Benevolent AI's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.171	+	4.839)	/	156.748
	=	0.04

Benevolent AI (GREY:BAIVF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Benevolent AI Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Benevolent AI's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Benevolent AI (Benevolent AI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benevolent AI (GREY:BAIVF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

BAI:Netherlands 2XA:Germany

Address

4-8 Maple Street, London, GBR, W1T 5HD

Website

https://www.benevolent.com

Benevolent AI is a clinical-stage AI-enabled drug discovery company. It delivers novel drug candidates with a higher probability of clinical success than those developed using traditional methods. The Benevolent Platform powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains commercial collaborations with pharmaceutical companies.